8-K: Outset Medical Faces Nasdaq Delisting Notice Again Despite Recent Financing

Outset Medical receives a second Nasdaq delisting notice for failing to maintain the minimum bid price, while also reporting full year 2024 results and securing new financing.

Summary

• Outset Medical received a second notice from Nasdaq on February 24, 2025, for failing to comply with the minimum bid price requirement.
• The company has until August 25, 2025, to regain compliance, requiring its stock to meet or exceed $1.00 per share for at least 10 consecutive trading days.
• If compliance isn't met, Outset may apply to transfer its listing to the Nasdaq Capital Market for an additional compliance period.
• A special stockholder meeting is scheduled for March 5, 2025, to vote on a potential reverse stock split, with a ratio between 1-for-10 and 1-for-15.
• There is no guarantee that the reverse stock split will be approved or that it will ensure compliance with Nasdaq listing rules.
• The company's management concluded that its disclosure controls and procedures were effective as of December 31, 2024.
• Management also concluded that its internal control over financial reporting was effective as of December 31, 2024.
• The company reported a net loss of $128.0 million for the year ended December 31, 2024, compared to a net loss of $172.8 million in 2023.
• In January 2025, Outset Medical entered into securities purchase agreements for a private placement, raising $168.8 million before expenses.
• Also in January 2025, the company secured a $100 million 5-year term loan with an option for an additional $25 million until July 14, 2027.
• The company terminated its previous credit facilities with SLR Investment Corp. and ABL lender.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company has secured new financing, it faces significant challenges, including a second Nasdaq delisting notice and continued operating losses. The potential reverse stock split adds further uncertainty.

Positives

• Outset Medical secured $168.8 million in gross proceeds through a private placement in January 2025.
• The company obtained a $100 million term loan in January 2025, with an option for an additional $25 million.
• The net loss for 2024 decreased to $128.0 million from $172.8 million in 2023.
• Management believes that the company's existing cash, cash equivalents, short-term investments, cash generated from sales, and proceeds recently received from the debt financing as well as proceeds received from the sale of Series A Preferred Stock will be sufficient to meet its anticipated needs for at least the next 12 months from the issuance date of the accompanying financial statements.
• Management concluded that its disclosure controls and procedures were effective as of December 31, 2024.
• Management also concluded that its internal control over financial reporting was effective as of December 31, 2024.

Negatives

• Outset Medical received a second Nasdaq delisting notice for failing to maintain the minimum bid price.
• The company has incurred net losses and negative cash flows from operations since inception.
• As of December 31, 2024, the company had an accumulated deficit of $1.1 billion.
• There is no guarantee that the reverse stock split will be approved or that it will ensure compliance with Nasdaq listing rules.
• The company is subject to a number of risks associated with operating its Mexico-based manufacturing facility.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting.
• The potential reverse stock split may not be approved by stockholders or may not be effective in raising the stock price.
• Continued operating losses and negative cash flows could strain the company's financial resources.
• The company's reliance on a manufacturing facility in Tijuana, Mexico, exposes it to various operational and regulatory risks.
• The company is involved in a purported stockholder class action lawsuit and a derivative action, which could result in significant costs and liabilities.

Future Outlook

Management expects to continue to incur operating losses in the near term while the Company makes investments to support its anticipated growth. Management believes that the Company's existing cash, cash equivalents, short-term investments, cash generated from sales, and proceeds recently received from the debt financing as well as proceeds received from the sale of Series A Preferred Stock will be sufficient to meet its anticipated needs for at least the next 12 months from the issuance date of the accompanying financial statements.

Industry Context

The medical technology industry is highly competitive, and Outset Medical faces competition from established dialysis providers and manufacturers. The company's ability to innovate and gain market share will be crucial for its long-term success. The regulatory landscape, including FDA approvals and reimbursement policies, also plays a significant role in the company's prospects.

Comparison to Industry Standards

• Outset Medical's financial performance can be compared to other medical device companies in the dialysis space, such as Baxter International and Fresenius Medical Care.
• These companies have significantly larger revenue bases and established market positions.
• Outset Medical's focus on home dialysis and technological innovation differentiates it from some competitors, but it also faces challenges in scaling its operations and gaining market acceptance.
• The company's cash burn rate and path to profitability will be key metrics to watch compared to industry benchmarks.

Legal Proceedings

• The company is involved in a purported stockholder class action lawsuit and a derivative action related to alleged false or misleading statements about the company's business, operations, and prospects.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may be affected by restructuring plans and workforce reductions.
• Customers may be concerned about the company's long-term viability and ability to provide ongoing support.
• Creditors are exposed to the risk of default if the company's financial performance does not improve.

Next Steps

• Stockholders will vote on a potential reverse stock split at a special meeting on March 5, 2025.
• The company must regain compliance with Nasdaq's minimum bid price requirement by August 25, 2025.
• The company will need to execute its business plan and demonstrate progress towards profitability to improve investor confidence.
• The company is required to prepare and file an initial registration statement with the SEC as soon as reasonably practicable, but in no event later than 60 days after the closing of the Private Placement, and to use best efforts to have the registration statement declared effective within 50 days after the filing of the initial registration statement with the SEC, subject to the approval of the conversion of the Series A Preferred Stock being received at the Companys special meeting of stockholders.

Key Dates

Keywords

Outset Medical, Nasdaq, Delisting, Minimum Bid Price, Reverse Stock Split, Private Placement, Term Loan, Financial Results, Compliance, Series A Preferred Stock